Wednesday, April 24, 2024

Cerevance Announces Presentation at the SFN Neuroscience 2023 Annual Meeting

Cerevance Announces Presentation at the SFN Neuroscience 2023 Annual Meeting


BOSTON, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Cerevance, a company focused on developing novel precision therapeutics for central nervous system (CNS) diseases, today announced plans to present a poster presentation at the Neuroscience 2023 Annual Meeting presented by the Society for Neuroscience, taking place in Washington, D.C., November 11 – 15th, 2023.

Presentation details

Title: NETSseq platform identifies the astrocyte specific potassium channel KCNJ10 (kir4.1) as a target for the potential treatment of neurodegenerative diseases
Overview: Gene expression relevant to human disease pathology can be observed using Cerevance's proprietary NETSseq platform. Data from this approach demonstrated that KCNJ10 is expressed in astrocytes from post-mortem brain tissue of Alzheimer's and Parkinson's disease donors and is increased in disease. Given that KCNJ10 is a central hub of many pathways significantly impacted by CNS diseases, including glutamate uptake, targeting this gene may present a novel approach ...

Full story available on Benzinga.com

Disclaimer: The views, recommendations, and opinions expressed in this content belong solely to the third-party experts. This site was not involved in the writing and production of this article.


Disclaimer Press Release Banner